In a Phase I clinical study, prexasertib was tested in combination with the PD-L1 inhibitor pembrolizumab, showing clinical benefit in 8 out of 14 patients with recurrent ovarian cancer, including patients with significant partial responses. The gene discussed is CD274; the disease is ovarian carcinoma.